Krystal Biotech, Inc. Common Stock (KRYS) — 分析摘要
Krystal Biotech, Inc. Common Stock（KRYS）的市值为10.71十亿美元，最近一年的营收同比增长了+33.9%。净利润率为52.6%。当前市盈率为47.6倍。
核心要点
- 营收同比变化+33.9%
- 净利润率52.6%
- 市盈率47.6倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，KRYS的营收增长为+33.9%，市盈率为47.6倍。
Krystal Biotech, Inc. Common Stock (KRYS)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
营业利润率 (42.8%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
295
总部
PITTSBURGH, PA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。